CXCR4 and neoplasm: In vivo, the nanocarriers mainly accumulated in tumor tissues (>75% of the administered dose) compared to non-tumor bearing organs, displaying a potent CXCR4-dependant antitumor effect in the absence of systemic toxicity in several CXCR4+ subcutaneous solid tumor mouse models (Sánchez-García et al., 2018; Serna et al., 2020; Voltà-Durán et al., 2021; Rioja-Blanco et al., 2022b; Falgàs et al., 2022).